Functional analysis of MAT2A in ovarian cancer development

• Project/Area Number: 23791804
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Tohoku University
• Principal Investigator: OTSUKI Takeo 東北大学, 医学(系)研究科(研究院), 非常勤講師 (40531330)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: エピジェネティクス / 卵巣がん / MAT2A

Research Abstract

Genome-wide epigenetic changes are involved in human ovarian cancer. In this study, we found that MAT2A (methyonine adenosyltransferase 2A), which produces a methyl donor for transmethylation and plays an important role in DNA and histone methylation, is highly expressed and its gene body region is hypomethylation in human ovarian cancer cells. MAT2A siRNA and its inhibitor (cycloroicine) suppressed ovarian cancer cell growth. We found that tumor suppressor gene RB1 is a molecular target of MAT2A for human ovarian cancer. Our data suggest that RB1 is the new tumor maker of human ovarian cancer.

Research Products

• [Journal Article] A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). (2014)
  • Author(s): Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama T.
  • Journal Title: Cancer Chemother Pharmacol Volume: - Issue: 5 Pages: 895-901
  • DOI: 10.1007/s00280-014-2418-8
  • Peer Reviewed
• [Journal Article] A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study) (2014)
  • Author(s): Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama T.
  • Journal Title: Cancer Chemother Pharmacol Volume: accepted
  • Peer Reviewed
• [Journal Article] Small cell carcinoma of the uterine cervix : clinical outcome of concurrent chemoradiotherapy with a multidrug regimen (2013)
  • Author(s): Tokunaga H, Nagase S, Yoshinaga K, Tanaka S, Nagai T, Kurosawa H, Kaiho-Sakuma M, Toyoshima M, Otsuki T, Utsunomiya H, Takano T, Niikura H, Ito K, Yaegashi N
  • Journal Title: Tohoku J Exp Med Volume: 229(1), PMID:23269283 Pages: 75-81
  • Peer Reviewed
• [Journal Article] Small cell carcinoma of the uterine cervix: clinical outcome of concurrent chemoradiotherapy with a multidrug regimen. (2013)
  • Author(s): Tokunaga H, Nagase S, Yoshinaga K, Tanaka S, Nagai T, Kurosawa H, Kaiho-Sakuma M, Toyoshima M, Otsuki T, Utsunomiya H, Takano T, Niikura H, Ito K, Yaegashi N.
  • Journal Title: Tohoku J Exp Med Volume: 229(1) Pages: 75-81
  • Peer Reviewed